{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:51:22Z","timestamp":1791553882311,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03816-9","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:16:35Z","timestamp":1791551795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of Ravulizumab Use in Pregnancy: Insights from a Global Pharmacovigilance Analysis"],"prefix":"10.1007","author":[{"given":"Cynthia","family":"Carrillo Infante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad","family":"Mujeebuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Koneru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"3816_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1643896","volume":"16","author":"RM Burwick","year":"2025","unstructured":"Burwick RM, Java A, Regal JF. The role of complement in normal pregnancy and preeclampsia. Front Immunol. 2025;16:1643896.","journal-title":"Front Immunol"},{"key":"3816_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.molimm.2015.02.030","volume":"67","author":"JF Regal","year":"2015","unstructured":"Regal JF, Gilbert JS, Burwick RM. The complement system and adverse pregnancy outcomes. Mol Immunol. 2015;67:56\u201370.","journal-title":"Mol Immunol"},{"key":"3816_CR3","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1002\/ajh.26854","volume":"98","author":"J Leon","year":"2023","unstructured":"Leon J, LeStang M, Sberro-Soussan R, et al. Complement-driven hemolytic uremic syndrome. Am J Hematol. 2023;98:S44-56.","journal-title":"Am J Hematol"},{"key":"3816_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1526317","volume":"16","author":"I Michailidou","year":"2025","unstructured":"Michailidou I, Patsiarika A, Kesidou E, et al. The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player? Front Immunol. 2025;16:1526317.","journal-title":"Front Immunol"},{"key":"3816_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/1744666X.2022.2105205","volume":"18","author":"P Stathopoulos","year":"2022","unstructured":"Stathopoulos P, Dalakas MC. The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders. Expert Rev Clin Immunol. 2022;18:933\u201345.","journal-title":"Expert Rev Clin Immunol"},{"key":"3816_CR6","doi-asserted-by":"publisher","first-page":"11438","DOI":"10.1182\/blood-2022-166545","volume":"140","author":"JE Manning","year":"2022","unstructured":"Manning JE, Ciantar E, Griffin M, Kelly R. Pregnancy in paroxysmal nocturnal hemoglobinuria\u2014a systematic review. Blood. 2022;140:11438\u201340.","journal-title":"Blood"},{"key":"3816_CR7","doi-asserted-by":"publisher","first-page":"S437","DOI":"10.1016\/j.ajog.2022.11.758","volume":"228","author":"A Tzur","year":"2023","unstructured":"Tzur A, Czuzoj-Shulman N, Abenhaim HA. Atypical hemolytic uremic syndrome and pregnancy outcomes: a cohort study. Am J Obstet Gynecol. 2023;228:S437\u20138.","journal-title":"Am J Obstet Gynecol"},{"key":"3816_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208871","author":"P Ladha","year":"2025","unstructured":"Ladha P, Amatya S, Kagzi Y, et al. Pregnancy outcomes in neuromyelitis optica spectrum disorder: a meta-analysis of pharmacotherapeutic agents (P11-8.020). Neurology. 2025. https:\/\/doi.org\/10.1212\/WNL.0000000000208871.","journal-title":"Neurology"},{"key":"3816_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00404-024-07436-y","volume":"310","author":"J Draxler","year":"2024","unstructured":"Draxler J, Meisel A, Stascheit F, et al. Pregnancy in myasthenia gravis: a retrospective analysis of maternal and neonatal outcome from a large tertiary care centre in Germany. Arch Gynecol Obstet. 2024;310:277\u201384.","journal-title":"Arch Gynecol Obstet"},{"key":"3816_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000518171","volume":"146","author":"E Rondeau","year":"2022","unstructured":"Rondeau E, Ardissino G, Caby-Tosi M-P, et al. Pregnancy in women with atypical hemolytic uremic syndrome. Nephron. 2022;146:1\u201310.","journal-title":"Nephron"},{"key":"3816_CR11","doi-asserted-by":"crossref","unstructured":"Manning JE, Ciantar E, Griffin M, Kelly RJ. Paroxysmal nocturnal haemoglobinuria in pregnancy\u2014a systematic review with meta analysis. Ann Hematol. 2025;104(4):2517\u201325.","DOI":"10.1007\/s00277-025-06353-7"},{"key":"3816_CR12","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3324\/haematol.2010.037531","volume":"96","author":"S de Guibert","year":"2011","unstructured":"de Guibert S, de Latour RP, Varoqueaux N, et al. Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience. Haematologica. 2011;96:1276.","journal-title":"Haematologica"},{"key":"3816_CR13","first-page":"103","volume":"30","author":"JG Ray","year":"2000","unstructured":"Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis (Basel). 2000;30:103\u201317.","journal-title":"Haemostasis (Basel)"},{"key":"3816_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041403","volume":"104","author":"P Meena","year":"2025","unstructured":"Meena P, Gala R, Das RR, et al. Kidney and pregnancy outcomes in pregnancy-associated atypical hemolytic uremic syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2025;104:e41403.","journal-title":"Medicine (Baltimore)"},{"key":"3816_CR15","first-page":"111","volume":"7","author":"A Harazeen","year":"2024","unstructured":"Harazeen A, Valaparla VL, Reiley LE, Patel C. Myasthenia gravis in pregnancy. Asian J Res Rep Neurol. 2024;7:111\u201329.","journal-title":"Asian J Res Rep Neurol"},{"key":"3816_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00554","volume":"11","author":"NE Gilhus","year":"2020","unstructured":"Gilhus NE. Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol. 2020;11:554.","journal-title":"Front Neurol"},{"key":"3816_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13023-022-02205-z","volume":"17","author":"M Su","year":"2022","unstructured":"Su M, Liu X, Wang L, et al. Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis. Orphanet J Rare Dis. 2022;17:52.","journal-title":"Orphanet J Rare Dis"},{"key":"3816_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/1753495X211041899","volume":"15","author":"H Banner","year":"2022","unstructured":"Banner H, Niles KM, Ryu M, Sermer M, Bril V, Murphy KE. Myasthenia gravis in pregnancy: systematic review and case series. Obstet Med. 2022;15:108\u201317.","journal-title":"Obstet Med"},{"key":"3816_CR19","doi-asserted-by":"publisher","first-page":"e2225438","DOI":"10.1001\/jamanetworkopen.2022.25438","volume":"5","author":"L Wang","year":"2022","unstructured":"Wang L, Su M, Zhou Z, et al. Analysis of pregnancy-related attacks in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. JAMA Netw Open. 2022;5:e2225438.","journal-title":"JAMA Netw Open"},{"key":"3816_CR20","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s40265-013-0147-7","volume":"73","author":"GM Keating","year":"2013","unstructured":"Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73:2053\u201366.","journal-title":"Drugs"},{"key":"3816_CR21","unstructured":"US Food and Drug Administration (FDA). Soliris (eculizumab) approval letter and prescribing information. Biologics License Application BLA 125166. Initial approval: 16 March 2007. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2007\/125166s0000_LTR.pdf. Accessed 11 Sept 2026."},{"key":"3816_CR22","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","volume":"373","author":"RJ Kelly","year":"2015","unstructured":"Kelly RJ, H\u00f6chsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373:1032\u20139.","journal-title":"N Engl J Med"},{"key":"3816_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Soci\u00e9","year":"2019","unstructured":"Soci\u00e9 G, Caby-Tosi M, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185:297\u2013310.","journal-title":"Br J Haematol"},{"key":"3816_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000543216","volume":"17","author":"N Khalil","year":"2025","unstructured":"Khalil N, Guerra Hernandez C, Farias J, et al. Safety and effectiveness of eculizumab throughout three pregnancies in a patient with refractory generalized myasthenia gravis: a case report. Case Rep Neurol. 2025;17:25\u201330.","journal-title":"Case Rep Neurol"},{"key":"3816_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100855","volume":"6","author":"BP Dixon","year":"2024","unstructured":"Dixon BP, Kavanagh D, Aris ADM, et al. Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase\u00a03 trials. Kidney Med. 2024;6:100855.","journal-title":"Kidney Med"},{"key":"3816_CR26","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1:EVIDoa2100066.","journal-title":"NEJM Evid"},{"key":"3816_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93:1053\u201368.","journal-title":"Ann Neurol"},{"key":"3816_CR28","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/j.ajog.2023.11.227","volume":"230","author":"H Shalev-Ram","year":"2024","unstructured":"Shalev-Ram H, Gabay N, Ram S, et al. 205 predicting miscarriage risk in individuals with chronic illnesses. Am J Obstet Gynecol. 2024;230:S125.","journal-title":"Am J Obstet Gynecol"},{"key":"3816_CR29","unstructured":"ULTOMIRIS\u00ae(ravulizumab-cwvz) injection, for intravenous use. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761108s041lbl.pdf. Accessed 11 Sept 2026."},{"key":"3816_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2025-001286","volume":"7","author":"A Jacob","year":"2025","unstructured":"Jacob A, Mahmoud A, Eldweik L, Mubashir A. Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report. BMJ Neurol Open. 2025;7:e001286.","journal-title":"BMJ Neurol Open"},{"key":"3816_CR31","doi-asserted-by":"crossref","unstructured":"F\u00fcreder W, Granser S, Repa A, Farr A. Ravulizumab exposure in early pregnancy. Ann Hematol. 2025;104(11):6081\u20134.","DOI":"10.1007\/s00277-025-06586-6"},{"key":"3816_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-026-04950-w","author":"A Alkhaldi","year":"2026","unstructured":"Alkhaldi A, Elawad M, Al Dalbhi S, Alquraini B, Alshannan A. A case report on the effective and safe use of ravulizumab in atypical hemolytic uremic syndrome during pregnancy. BMC Nephrol. 2026. https:\/\/doi.org\/10.1186\/s12882-026-04950-w.","journal-title":"BMC Nephrol"},{"key":"3816_CR33","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1182\/blood-2024-208645","volume":"144","author":"D Knight","year":"2024","unstructured":"Knight D, Patel BJ. Ravulizumab treatment during pregnancy: a case report. Blood. 2024;144:5688.","journal-title":"Blood"},{"key":"3816_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-025-06193-5","volume":"104","author":"A Kulasekararaj","year":"2025","unstructured":"Kulasekararaj A, Brodsky R, Schrezenmeier H, et al. Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2025;104:81\u201394.","journal-title":"Ann Hematol"},{"key":"3816_CR35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025019253","author":"B H\u00f6chsmann","year":"2026","unstructured":"H\u00f6chsmann B, Gerber GF, Leopold W, et al. Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy. Blood Adv. 2026. https:\/\/doi.org\/10.1182\/bloodadvances.2025019253.","journal-title":"Blood Adv"},{"key":"3816_CR36","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/bcp.14565","volume":"87","author":"GAM Eliesen","year":"2021","unstructured":"Eliesen GAM, van Drongelen J, van den Broek PHH, et al. Placental disposition of eculizumab, C5 and C5-eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria. Br J Clin Pharmacol. 2021;87:2128\u201331.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03816-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03816-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03816-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:16:36Z","timestamp":1791551796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03816-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":36,"alternative-id":["3816"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03816-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Cynthia Carrillo Infante, Arshad Mujeebuddin, Meghana Koneru, and Cory Williams are employees of Alexion, AstraZeneca Rare Disease, Boston, MA, USA. Cynthia Carrillo Infante, Arshad Mujeebuddin, and Cory Williams hold stocks options and shares in Alexion.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require approval by an independent ethics committee (IEC)\/institutional review board (IRB) or informed consent, since it utilized fully anonymized secondary data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The pharmacovigilance database used in this study is owned by Alexion, AstraZeneca Rare Disease, and no permissions were required for access and use.","order":3,"name":"Ethics","label":"Declaration on Database Use","group":{"name":"EthicsHeading","label":"Declarations"}}]}}